RXRX supply chain intelligence for Recursion Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Recursion Pharmaceuticals, Inc. (RXRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CONTRACT-DEVELOPMENT-AND-MANUFACTURING-ORGANIZAT | CONTRACT-DEVELOPMENT-AND-MANUFACTURING-ORGANIZAT | 90% | We currently utilize contract development and manufacturing organizations to produce drug substance and investigational drug product in support of the assets within our pipeline. |
| GOOGLE-CLOUD | GOOGLE-CLOUD | 90% | In October 2024, we announced an expanded collaboration with Google Cloud leveraging their technologies to accelerate drug discovery research and further enhance our ability to bring new medicines to… |
| HELIX | HELIX | 90% | In May 2024, we entered into a multi-year agreement with Helix to access hundreds of thousands of de-identified clinic-genomic records consisting of longitudinal clinical records paired with Helix’s … |
| NVDA | NVIDIA Corporation | 90% | Reciprocal relationship from NVDA graph: Reciprocal relationship from RXRX graph: Reciprocal relationship from NVDA graph: Reciprocal relationship from RXRX graph: Reciprocal relationship from NVDA g… |
| NVDA | NVIDIA Corporation | 90% | In July 2023, we entered a strategic collaboration with NVIDIA to accelerate the development of our groundbreaking AI foundation models for biology and chemistry using our supercomputer, BioHive-1, a… |
| TAKEDA | TAKEDA | 90% | During a collaboration with Takeda, we leveraged machine vision and automated analysis to quantify hundreds of cellular parameters linked to APC siRNA knockdown. |
| BDRX | Biodexa Pharmaceuticals Plc | 72% | Reciprocal relationship from BDRX graph: ddition of additional warnings, contraindications or other safety information, including boxed warnings; · suspend, vary or withdraw regulatory approval; · re… |
| EVO | Evotec SE | 72% | Reciprocal relationship from EVO graph: o our revenue was 74 and 109 in 2025 and 2024, respectively (2023:102). Evotec’s largest three customers by revenue collectively accounted for 43% of revenues … |
| SDGR | Schrödinger, Inc. | 72% | Reciprocal relationship from SDGR graph: Reciprocal relationship from RXRX graph: Reciprocal relationship from SDGR graph: Reciprocal relationship from RXRX graph: Reciprocal relationship from SDGR g… |
| TEM | Tempus AI, Inc. | 72% | Reciprocal relationship from TEM graph: e us to successfully deliver results over 98% of the time, assuming tissue is received that meets the minimum requirements we have outlined for our assays. Our… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ROCHE | ROCHE | 92% | our collaboration with Roche and Genentech achieved a groundbreaking milestone: the world’s first genome-scale Neuromap, a comprehensive AI-powered model of neurobiology built from human-induced plur… |
| SANOFI | SANOFI | 90% | our work with Sanofi continues to drive value. In 2024, we received $15 million in milestone payments after advancing two discovery programs into lead optimization, each showing strong differentiatio… |
| GENENTECH | GENENTECH | 85% | our collaboration with Roche and Genentech achieved a groundbreaking milestone: the world’s first genome-scale Neuromap, a comprehensive AI-powered model of neurobiology built from human-induced plur… |
| SNYNF | Sanofi | 85% | mercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market, and sell our drug product candidates, and to use our proprietary technologies, without… |
| SNYNF | Sanofi | 85% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from RXRX graph: mercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market, and… |
| BAYER | BAYER | 80% | we continue to collaborate with leading biopharma partners like Roche and Genentech, Sanofi, Bayer, and Merck KGaA, Darmstadt, Germany. |
| MERCK-KGAA-DARMSTADT-GERMANY | MERCK-KGAA-DARMSTADT-GERMANY | 80% | we continue to collaborate with leading biopharma partners like Roche and Genentech, Sanofi, Bayer, and Merck KGaA, Darmstadt, Germany. |
| BDRX | Biodexa Pharmaceuticals Plc | 72% | Reciprocal relationship from BDRX graph: Reciprocal relationship from RXRX graph: Reciprocal relationship from BDRX graph: Reciprocal relationship from RXRX graph: Reciprocal relationship from BDRX g… |
| SDGR | Schrödinger, Inc. | 72% | Reciprocal relationship from SDGR graph: g technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success i… |
| TEM | Tempus AI, Inc. | 72% | Reciprocal relationship from TEM graph: e us to successfully deliver results over 98% of the time, assuming tissue is received that meets the minimum requirements we have outlined for our assays. Our… |
| TEM | Tempus AI, Inc. | 72% | presented. Revenue and net loss for any interim period are not necessarily indicative of future or annual results. Recent Accounting Pronouncements In December 2025, the FASB issued ASU No. 2025-10, … |
| ALLCYTE-GMBH | ALLCYTE-GMBH | 62% | , Cyclica, and Valence, a greater portion of Recursion’s business takes place in international markets. Recursion will conduct its business and prepare its consolidated financial statements in its fu… |
| ALPHA-BIOTECHNOLOGY-GMBH | ALPHA-BIOTECHNOLOGY-GMBH | 62% | presented. Revenue and net loss for any interim period are not necessarily indicative of future or annual results. Recent Accounting Pronouncements In December 2025, the FASB issued ASU No. 2025-10, … |
| CATALYST-PHARMS-INC | CATALYST-PHARMS-INC | 62% | ary for us to begin selling them. We have not conducted, managed or completed large-scale or pivotal clinical trials nor managed the regulatory approval process with the FDA or any other regulatory a… |
| EXSCIENTIA-GMBH | EXSCIENTIA-GMBH | 62% | he three months ended March 31, 2025, was primarily driven by a decrease in salaries of $6.7 million as a result of headcount reductions in the year, in addition to one-time transaction costs in the … |
| VALENCE-DISCOVERY-INC | VALENCE-DISCOVERY-INC | 62% | nting policies, and applying the acquisition method of accounting at January 1, 2023. Recursion incurred approximately $ 20.5 million of transaction costs which are presented in general and administr… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| RXRX-DEBT | Debt stack $723,000 | 90% | Market cache reports total debt of $723,000. |
| RXRX-DEBT-12326 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2022-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| RXRX-OWNER-BAILLIE-GIFFORD-CO | BAILLIE GIFFORD & CO | 95% | 13F/ownership overlay lists BAILLIE GIFFORD & CO; shares held 23,774,972; ownership 4.56%; value $82.1M; as of 2025-12-31. |
| RXRX-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 10,934,252; ownership 2.09%; value $37.8M; as of 2025-12-31. |
| RXRX-OWNER-BLACKROCK-INC | Blackrock Inc. | 95% | 13F/ownership overlay lists Blackrock Inc.; shares held 38,866,779; ownership 7.45%; value $134.3M; as of 2025-12-31. |
| RXRX-OWNER-STATE-STREET-CORPORATION | State Street Corporation | 95% | 13F/ownership overlay lists State Street Corporation; shares held 25,333,888; ownership 4.85%; value $87.5M; as of 2025-12-31. |
| RXRX-OWNER-ARK-INVESTMENT-MANAGEMENT-LLC | ARK Investment Management, LLC | 95% | 13F/ownership overlay lists ARK Investment Management, LLC; shares held 37,316,856; ownership 7.15%; value $128.9M; as of 2025-12-31. |
| RXRX-OWNER-KINNEVIK-AB-PUBL | Kinnevik Ab (publ) | 95% | 13F/ownership overlay lists Kinnevik Ab (publ); shares held 13,434,171; ownership 2.57%; value $46.4M; as of 2025-09-30. |
| RXRX-OWNER-MIC-CAPITAL-MANAGEMENT-UK-LLP | MIC Capital Management UK LLP | 95% | 13F/ownership overlay lists MIC Capital Management UK LLP; shares held 9,644,032; ownership 1.85%; value $33.3M; as of 2025-12-31. |
| RXRX-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 47,187,759; ownership 9.04%; value $163.0M; as of 2025-12-31. |
| RXRX-OWNER-SOFTBANK-GROUP-CORPORATION | Softbank Group Corporation | 95% | 13F/ownership overlay lists Softbank Group Corporation; shares held 13,636,515; ownership 2.61%; value $47.1M; as of 2025-12-31. |
| RXRX-OWNER-AMOVA-ASSET-MANAGEMENT-AMERICAS-INC | Amova Asset Management Americas Inc | 95% | 13F/ownership overlay lists Amova Asset Management Americas Inc; shares held 6,221,025; ownership 1.19%; value $21.5M; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| FULC | Fulcrum Therapeutics, Inc. | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| GRAL | GRAIL, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 |